Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIVassociated NHL, and that infusional chemotherapy may be more effective. We...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sparano, Joseph A., Lee, Jeannette Y., Kaplan, Lawrence D., Levine, Alexandra M., Ramos, Juan Carlos, Ambinder, Richard F., Wachsman, William, Aboulafia, David, Noy, Ariela, Henry, David H., Von Roenn, Jamie, Dezube, Bruce J., Remick, Scot C., Shah, Manisha H., Leichman, Lawrence, Ratner, Lee, Cesarman, Ethel, Chadburn, Amy, Mitsuyasu, Ronald
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2010
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2858478/
https://ncbi.nlm.nih.gov/pubmed/20023215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-08-231613
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires